MindMed (MNMD) Stock Rises 154% in 3 Months: Here's WhyZacks Investment Research • 16 days ago
Shares of Mind Medicine (MindMed) Inc. MNMD have skyrocketed 154% in the past three months against the industry's decline of 4.2%.The company is progressing well with the development of its lead...
Share to Feed
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade...
ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 7,990,000 shares, a growth of 18.9% from the...
This is a signal that ADMA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This price move could be a signal that ADMA may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...
Shares of Moderna MRNA rose 3% on Wednesday after management announced positive clinical updates at its Vaccines Day Event, highlighting its pipeline progress.While the company provided an update on...
Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...
Syndax Pharmaceuticals SNDX stock rose 7.6% on Mar 27 after it announced a day before that the FDA had granted a priority review to its new drug application (NDA) for pipeline candidate revumenib...
This is a signal that ADMA's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...
This is a signal that ADMA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...